10 results
Pain Assessment and Management Initiative (PAMI) - Neuropathic Pain Medications:

Agent, Initiation Dose and Max Dosages

 -
Management Initiative (PAMI ... Agent, Initiation Dose ... Management #Pain #Pharmacology ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Transdermal Medications

#Management #Pain #Pharmacology #Transdermal #Topical #Medications #Doses #Dosing
Pain Assessment and ... Management Initiative (PAMI ... Management #Pain #Pharmacology ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Non-Opioid Analgesics - Agents and Dosing

#Management #Pain #Pharmacology #NonOpioid
Dosing #Management ... #Pain #Pharmacology ... NonOpioid #Analgesics #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Muscle Relaxants - Agents and Dosing

#Management #Pain #Pharmacology #Muscle
Dosing #Management ... #Pain #Pharmacology ... Relaxers #Relaxants #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Nerve Blocks - Nerve Distribution, Agents and Dosing Table
Dosing Table - ... Management #Pain #Pharmacology ... Nerve #Blocks #Medications ... #Doses #Dosing ... #Table #PAMI
Pain Assessment and Management Initiative (PAMI) - Intranasal and Nebulized Medications- Agents and Dosing

#Management #Pain #Pharmacology
Nebulized Medications ... - Agents and Dosing ... Management #Pain #Pharmacology ... #Doses #Dosing ... #Table #PAMI
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... insulin by ~20% • Never ... Adjust insulin dose ... #pharmacology # ... comparison #table
Potassium-Binding Agents to Treat Hyperkalemia
Sodium zirconium cyclosilicate (Lokelma):
 • Mechanism: Preferentially captures K in exchange for
sodium • Dosing ... #Hyperkalemia #medications ... #pharmacology # ... table #comparison ... #binders
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
GLP-1 Agonist Dosing ... drug to remain stable ... patients to take meds ... #semaglutide #Diabetes ... #Pharmacology #
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
or family - Ever ... - Allergies to medications ... event, follow ACC algorithm ... Cataract Plan for Meds ... Diabetes regimen